nach oben

26.04.2024 | REVIEW

Bacillus Calmette-Guérin (BCG)-Induced Protection in Brain Disorders

verfasst von: Khiany Mathias, Richard Simon Machado, Solange Stork, Carla Damasio Martins, Amanda Christine da Silva Kursancew, Victória Linden de Rezende, Cinara Ludvig Gonçalves, Tatiana Barichello, Josiane Somariva Prophiro, Fabricia Petronilho

Erschienen in: Inflammation

Einloggen, um Zugang zu erhalten

Abstract

The Bacille Calmette-Guerin (BCG) vaccine is one of the most widely used vaccines in the world for the prevention of tuberculosis. Its immunological capacity also includes epigenetic reprogramming, activation of T cells and inflammatory responses. Although the main usage of the vaccine is the prevention of tuberculosis, different works have shown that the effect of BCG can go beyond the peripheral immune response and be linked to the central nervous system by modulating the immune system at the level of the brain. This review therefore aims to describe the BCG vaccine, its origin, its relationship with the immune system, and its involvement at the brain level.

Andersen, P., and T.M. Doherty. 2005. The success and failure of BCG — implications for a novel tuberculosis vaccine. Nature Reviews. Microbiology 3 (8): 656–662.PubMedCrossRef

Fatima, S., A. Kumari, G. Das, and V.P. Dwivedi. 2020. Tuberculosis vaccine: a journey from BCG to present. Life Sciences 252: 117594.PubMedCrossRef

Moreo, E., A. Jarit-Cabanillas, I. Robles-Vera, S. Uranga, C. Guerrero, A.B. Gómez, et al. 2023. Intravenous administration of BCG in mice promotes natural killer and T cell-mediated antitumor immunity in the lung. Nature Communications 14 (1): 6090.PubMedPubMedCentralCrossRef

Tran, Kim A., E. Pernet, M. Sadeghi, J. Downey, J. Chronopoulos, E. Lapshina, O. Tsai, E. Kaufmann, J. Ding, and M. Divangahi. 2024. BCG immunization induces CX3CR1hi effector memory T cells to provide cross-protection via IFN-γ-mediated trained immunity. Nature Immunology 25: 418–431

Jeyanathan, M., M. Vaseghi-Shanjani, S. Afkhami, J.A. Grondin, A. Kang, M.R. D’Agostino, et al. 2022. Parenteral BCG vaccine induces lung-resident memory macrophages and trained immunity via the gut–lung axis. Nature Immunology 23 (12): 1687–1702.PubMedPubMedCentralCrossRef

Singh, Alok K., R. Wang, K.A Lombardo, M. Praharaj, C.K. Bullen, P. Um, S. Davis, et al. 2022. Dynamic single-cell RNA sequencing reveals BCG vaccination curtails SARS-CoV-2 induced disease severity and lung inflammation. biorxiv: the Preprint Server for Biology. Mar 15. https://doi.org/10.1101/2022.03.15.484018

Rakshit, S., V. Adiga, A. Ahmed, C. Parthiban, N.C. Kumar, P. Dwarkanath, S. Shivalingaiah, et al. 2022. BCG revaccination qualitatively and quantitatively enhances SARS-CoV-2 spike-specific neutralizing antibody and T cell responses induced by the COVISHIELDTM vaccine in SARS-CoV-2 seronegative young Indian adults. Research Square. Mar 2. https://doi.org/10.21203/rs.3.rs-1395683/v1

Kowalewicz-Kulbat, M., and C. Locht. 2017. BCG and protection against inflammatory and auto-immune diseases. Expert Review of Vaccines 16 (7): 699–708.CrossRef

Yong, J., G. Lacan, H. Dang, T. Hsieh, B. Middleton, C. Wasserfall, et al. 2011. BCG vaccine-induced neuroprotection in a mouse model of Parkinson’s disease. PLoS One 6 (1): e16610.PubMedPubMedCentralCrossRef

10.

Li, Q., Y. Zhang, J. Zou, F. Qi, J. Yang, Q. Yuan, et al. 2016. Neonatal vaccination with bacille Calmette-Guérin promotes the dendritic development of hippocampal neurons. Human Vaccines & Immunotherapeutics 12 (1): 140–149.CrossRef

11.

Han, J., X. Gu, Y. Li, and Q. Wu. 2020. Mechanisms of BCG in the treatment of bladder cancer-current understanding and the prospect. Biomedicine & Pharmacotherapy 129: 110393.CrossRef

12.

Radhakrishnan, R.K., R.S. Thandi, D. Tripathi, P. Paidipally, M.K. McAllister, S. Mulik, et al. 2020. BCG vaccination reduces the mortality of Mycobacterium tuberculosis–infected type 2 diabetes mellitus mice. JCI Insight 5 (5).

13.

Brook, B., D.J. Harbeson, C.P. Shannon, B. Cai, D. He, R. Ben-Othman, et al. 2020. BCG vaccination–induced emergency granulopoiesis provides rapid protection from neonatal sepsis. Science Translational Medicine 12 (542).

14.

Faustman, D.L., A. Lee, E.R. Hostetter, A. Aristarkhova, N.C. Ng, G.F. Shpilsky, et al. 2022. Multiple BCG vaccinations for the prevention of COVID-19 and other infectious diseases in type 1 diabetes. Cell Reports Medicine 3 (9): 100728.PubMedPubMedCentralCrossRef

15.

Cossu, D., S. Ruberto, K. Yokoyama, N. Hattori, and L.A. Sechi. 2022. Efficacy of BCG vaccine in animal models of neurological disorders. Vaccine 40 (3): 432–436.PubMedCrossRef

16.

Zuo, Z., F. Qi, Z. Xing, L. Yuan, Y. Yang, Z. He, et al. 2021. Bacille Calmette-Guérin attenuates vascular amyloid pathology and maximizes synaptic preservation in APP/PS1 mice following active amyloid-β immunotherapy. Neurobiology of Aging 101: 94–108.PubMedCrossRef

17.

Gofrit, O.N., H. Bercovier, B.Y. Klein, I.R. Cohen, T. Ben-Hur, and C.L. Greenblatt. 2019. Can immunization with Bacillus Calmette-Guérin (BCG) protect against Alzheimer’s disease? Medical Hypotheses 123: 95–97.PubMedCrossRef

18.

Yedke, N.G., D. Soni, and P. Kumar. 2023. Effect of Bacille‐Calmette‐Guerin vaccine against rotenone‐induced Parkinson’s disease: role of neuroinflammation and neurotransmitters. Fundamental & Clinical Pharmacology. Dec 2. https://doi.org/10.1111/fcp.12968

19.

Schaltz-Buchholzer, F., M. Kjær Sørensen, C.S. Benn, and P. Aaby. 2022. The introduction of BCG vaccination to neonates in Northern Sweden, 1927–31: re-analysis of historical data to understand the lower mortality among BCG-vaccinated children. Vaccine 40 (11): 1516–1524.PubMedCrossRef

20.

Chen, J., L. Gao, X. Wu, Y. Fan, M. Liu, L. Peng, et al. 2023. BCG-induced trained immunity: history, mechanisms and potential applications. Journal of Translational Medicine 21 (1): 106.PubMedPubMedCentralCrossRef

21.

Li, J., J. Lu, G. Wang, A. Zhao, and M. Xu. 2022. Past, present and future of Bacillus Calmette-Guérin vaccine use in China. Vaccines (Basel). 10 (7): 1157.PubMedPubMedCentralCrossRef

22.

Singh, A.K., M.G. Netea, and W.R. Bishai. 2021. BCG turns 100: its nontraditional uses against viruses, cancer, and immunologic diseases. Journal of Clinical Investigation 131 (11).

23.

Calmette, A., C. Guerin, and B. Weill-Halle. 1924. Essai d’immunisation contre l’infection tuberculeuse. Bulletin de l’Académie Nationale de Médecine 91: 787–796.

24.

Mangtani, P., I. Abubakar, C. Ariti, R. Beynon, L. Pimpin, P.E.M. Fine, et al. 2014. Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clinical Infectious Diseases 58 (4): 470–480.PubMedCrossRef

25.

Corner, L.A.L., B.M. Buddle, D.U. Pfeiffer, and R.S. Morris. 2001. Aerosol vaccination of the brushtail possum (Trichosurus vulpecula) with bacille Calmette–Guérin: the duration of protection. Veterinary Microbiology 81 (2): 181–191.PubMedCrossRef

26.

Elton, L., S. Kasaragod, H. Donoghue, H.A. Safar, P. Amankwah, A. Zumla, et al. 2023. Mapping the phylogeny and lineage history of geographically distinct BCG vaccine strains. Microbial Genomics 9 (8).

27.

Luca, S., and T. Mihaescu. 2013. History of BCG vaccine. Maedica (Bucur) 8 (1): 53–68.PubMed

28.

Tran, V., J. Liu, and M.A. Behr. 2014. BCG vaccines. Molecular Genetics of Mycobacteria 2 (1).

29.

Lobo, N., N.A. Brooks, A.R. Zlotta, J.D. Cirillo, S. Boorjian, P.C. Black, et al. 2021. 100 years of Bacillus Calmette-Guérin immunotherapy: from cattle to COVID-19. Nature Reviews. Urology 18 (10): 611–622.PubMedPubMedCentralCrossRef

30.

Yamazaki-Nakashimada, M.A., A. Unzueta, L. Berenise Gámez-González, N. González-Saldaña, and R.U. Sorensen. 2020. BCG: a vaccine with multiple faces. Human Vaccines & Immunotherapeutics 16 (8): 1841–1850.CrossRef

31.

Rakshit, S., V. Adiga, A. Ahmed, C. Parthiban, N. Chetan Kumar, P. Dwarkanath, et al. 2022. Evidence for the heterologous benefits of prior BCG vaccination on COVISHIELD^TM vaccine-induced immune responses in SARS-CoV-2 seronegative young Indian adults. Frontiers in Immunology 4: 13.

32.

Kleinnijenhuis, J., J. Quintin, F. Preijers, C.S. Benn, L.A.B. Joosten, C. Jacobs, et al. 2014. Long-lasting effects of BCG vaccination on both heterologous Th1/Th17 responses and innate trained immunity. Journal of Innate Immunity 6 (2): 152–158.PubMedCrossRef

33.

Gela, A., M. Murphy, M. Rodo, K. Hadley, W.A. Hanekom, W.H. Boom, et al. 2022. Effects of BCG vaccination on donor unrestricted T cells in two prospective cohort studies. eBioMedicine 76: 103839.PubMedPubMedCentralCrossRef

34.

Kaufmann, E., J. Sanz, J.L. Dunn, N. Khan, L.E. Mendonça, A. Pacis, et al. 2018. BCG educates hematopoietic stem cells to generate protective innate immunity against tuberculosis. Cell 172 (1–2): 176-190.e19.PubMedCrossRef

35.

Cirovic, B., L.C.J. de Bree, L. Groh, B.A. Blok, J. Chan, W.J.F.M. van der Velden, et al. 2020. BCG vaccination in humans elicits trained immunity via the hematopoietic progenitor compartment. Cell Host & Microbe 28 (2): 322-334.e5.CrossRef

36.

Singh, A.K., M. Praharaj, K.A. Lombardo, T. Yoshida, A. Matoso, A.S. Baras, et al. 2022. Re-engineered BCG overexpressing cyclic di-AMP augments trained immunity and exhibits improved efficacy against bladder cancer. Nature Communications 13 (1): 878.PubMedPubMedCentralCrossRef

37.

Wang, Y., F. Ge, J. Wang, H. Li, B. Zheng, W. Li, et al. 2023. Mycobacterium bovis BCG given at birth followed by inactivated respiratory syncytial virus vaccine prevents vaccine-enhanced disease by promoting trained macrophages and resident memory t cells. Journal of Virology 97 (3).

38.

Koeken, V.A.C.M., A.J. Verrall, M.G. Netea, P.C. Hill, and R. van Crevel. 2019. Trained innate immunity and resistance to Mycobacterium tuberculosis infection. Clinical Microbiology and Infection 25 (12): 1468–1472.PubMedCrossRef

39.

Debisarun, P.A., G. Kilic, L.C.J. de Bree, L.J. Pennings, J. van Ingen, C.S. Benn, et al. 2023. The impact of BCG dose and revaccination on trained immunity. Clinical Immunology 246: 109208.PubMedCrossRef

40.

Moorlag, S.J.C.F.M., Y.A. Rodriguez-Rosales, J. Gillard, S. Fanucchi, K. Theunissen, B. Novakovic, et al. 2020. BCG vaccination induces long-term functional reprogramming of human neutrophils. Cell Reports 33 (7): 108387.PubMedCrossRef

41.

Sarfas, C., A.D. White, L. Sibley, A.L. Morrison, J. Gullick, S. Lawrence, et al. 2021. Characterization of the infant immune system and the influence and immunogenicity of BCG vaccination in infant and adult rhesus macaques. Frontiers in Immunology 11: 12.

42.

Kang, A., G. Ye, R. Singh, S. Afkhami, J. Bavananthasivam, X. Luo, et al. 223. Subcutaneous BCG vaccination protects against streptococcal pneumonia via regulating innate immune responses in the lung. EMBO Molecular Medicine 15 (7).

43.

Komine-Aizawa, S., S. Mizuno, A. Kawano, S. Hayakawa, K. Matsuo, and M. Honda. 2023. The induction of antigen 85B-specific CD8+ T cells by recombinant BCG protects against mycobacterial infection in mice. International Journal of Molecular Sciences 24 (2): 966.PubMedPubMedCentralCrossRef

44.

Aagaard, C., N.P.H. Knudsen, I. Sohn, A.A. Izzo, H. Kim, E.H. Kristiansen, et al. 2020. Immunization with Mycobacterium tuberculosis–specific antigens bypasses T cell differentiation from prior Bacillus Calmette-Guérin vaccination and improves protection in mice. The Journal of Immunology 205 (8): 2146–2155.PubMedPubMedCentralCrossRef

45.

Mathurin, K.S., G.W. Martens, H. Kornfeld, and R.M. Welsh. 2009. CD4 T-cell-mediated heterologous immunity between mycobacteria and poxviruses. Journal of Virology 83 (8): 3528–3539.PubMedPubMedCentralCrossRef

46.

Triglia, D., K.M. Gogan, J. Keane, and M.P. O’Sullivan. 2023. Glucose metabolism and its role in the maturation and migration of human CD1c+ dendritic cells following exposure to BCG. Frontiers in Cellular and Infection Microbiology 5: 13.

47.

Gonciarz, W., M. Chyb, and M. Chmiela. 2023. Mycobacterium bovis BCG increase the selected determinants of monocyte/macrophage activity, which were diminished in response to gastric pathogen Helicobacter pylori. Scientific Reports 13 (1): 3107.PubMedPubMedCentralCrossRef

48.

Peng, X., Y. Zhou, B. Zhang, X. Liang, J. Feng, Y. Huang, et al. 2024. Mucosal recombinant BCG vaccine induces lung-resident memory macrophages and enhances trained immunity via mTORC2/HK1-mediated metabolic rewiring. Journal of Biological Chemistry 300 (1): 105518.PubMedCrossRef

49.

Ahmed, A., H. Tripathi, K.E. van Meijgaarden, N.C. Kumar, v Adiga, S. Rakshit, et al. 2023. BCG revaccination in adults enhances pro-inflammatory markers of trained immunity along with anti-inflammatory pathways. iScience 26 (10): 107889.PubMedPubMedCentralCrossRef

50.

Narinyan, W., N. Poladian, D. Orujyan, A. Gargaloyan, and V. Venketaraman. 2022. Immunologic role of innate lymphoid cells against Mycobacterial tuberculosis Infection. Biomedicines. 10 (11): 2828.PubMedPubMedCentralCrossRef

51.

Kumar, N.P., C. Padmapriyadarsini, A. Rajamanickam, P.K. Bhavani, A. Nancy, B. Jayadeepa, et al. 2021. BCG vaccination induces enhanced frequencies of memory T cells and altered plasma levels of common γc cytokines in elderly individuals. PLoS One 16 (11): :e0258743.PubMedCrossRef

52.

Gerosa, F., B. Baldani-Guerra, C. Nisii, V. Marchesini, G. Carra, and G. Trinchieri. 2002. Reciprocal activating interaction between natural killer cells and dendritic cells. The Journal of Experimental Medicine 195 (3): 327–333.PubMedPubMedCentralCrossRef

53.

Feinberg, J., C. Fieschi, R. Doffinger, M. Feinberg, T. Leclerc, S. Boisson-Dupuis, et al. 2004. Bacillus Calmette Guérin triggers the IL-12/IFN-γ axis by an IRAK-4- and NEMO-dependent, non-cognate interaction between monocytes, NK, and T lymphocytes. European Journal of Immunology 34 (11): 3276–3284.PubMedCrossRef

54.

Perdomo, C., U. Zedler, A.A. Kühl, L. Lozza, P. Saikali, L.E. Sander, et al. 2016. Mucosal BCG vaccination induces protective lung-resident memory T cell populations against tuberculosis. mBio 7 (6).

55.

Li, Q., and H.-H. Shen. 2009. Neonatal bacillus Calmette-Guérin vaccination inhibits de novo allergic inflammatory response in mice via alteration of CD4+CD25+ T-regulatory cells. Acta Pharmacologica Sinica 30 (1): 125–133.PubMedCrossRef

56.

Aaby, P., A. Roth, H. Ravn, B.M. Napirna, A. Rodrigues, I.M. Lisse, et al. 2011. Randomized trial of BCG vaccination at birth to low-birth-weight children: beneficial nonspecific effects in the neonatal period? The Journal of Infectious Diseases 204 (2): 245–252.PubMedCrossRef

57.

Cancelier, A.C., F. Petronilho, A. Reinke, L. Constantino, R. Machado, C. Ritter, et al. 2009. Inflammatory and oxidative parameters in cord blood as diagnostic of early-onset neonatal sepsis: a case-control study. Pediatric Critical Care Medicine. 10 (4): 467–71.PubMedCrossRef

58.

Moorlag, S.J.C.F.M., R.J.W. Arts, R. van Crevel, and M.G. Netea. 2019. Non-specific effects of BCG vaccine on viral infections. Clinical Microbiology and Infection 25 (12): 1473–1478.PubMedCrossRef

59.

Sylvester, R.J., A.P.M. van der Meijden, J.A. Witjes, and K. Kurth. 2005. Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. Journal of Urology. 174 (1): 86–91.PubMedCrossRef

60.

Lamm, D.L., B.A. Blumenstein, J.D. Crissman, J.E. Montie, J.E. Gottesman, B.A. Lowe, et al. 2000. Maintenance Bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study. Journal of Urology 163 (4): 1124–1129.PubMedCrossRef

61.

Kleinnijenhuis, J., J. Quintin, F. Preijers, L.A.B. Joosten, D.C. Ifrim, S. Saeed, et al. 2012. Bacille Calmette-Guérin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proceedings of the National Academy of Sciences. 109 (43): 17537–17542.CrossRef

62.

Méndez-Samperio, P., A. Pérez, and L. Alba. 2010. Reactive oxygen species-activated p38/ERK 1/2 MAPK signaling pathway in the Mycobacterium bovis Bacillus Calmette Guérin (BCG)-induced CCL2 secretion in human monocytic cell line THP-1. Archives of Medical Research 41 (8): 579–585.PubMedCrossRef

63.

Méndez-Samperio, P., A. Pérez, and L. Torres. 2009. Role of reactive oxygen species (ROS) in Mycobacterium bovis Bacillus Calmette Guérin-mediated up-regulation of the human cathelicidin LL-37 in A549 cells. Microbial Pathogenesis 47 (5): 252–257.PubMedCrossRef

64.

Al-Humairi, R.M.A., T. Hashim Mohammad, S. Thanoon Ahmed, and Ad’hiah AH. 2023. Systemic interleukin-6 response after intravesical instillation of Bacillus Calmette-Guérin and mitomycin C in superficial bladder cancer. Archives of Razi Institute 78 (1): 353–360.PubMedPubMedCentral

65.

Koeken, V.A.C.M. 2021. Controlling inflammation in the elderly with BCG vaccination. Science Advances 7 (32).

66.

Koeken, V.A.C.M., L.C.J. de Bree, V.P. Mourits, S.J.C.F.M. Moorlag, J. Walk, B. Cirovic, et al. 2020. BCG vaccination in humans inhibits systemic inflammation in a sex-dependent manner. Journal of Clinical Investigation 130 (10): 5591–5602.PubMedPubMedCentralCrossRef

67.

Yang, W., Z. Dong, Y. Li, Y. Zhang, H. Fu, and Y. Xie. 2021. Therapeutic efficacy of chitosan nanoparticles loaded with BCG-polysaccharide nucleic acid and ovalbumin on airway inflammation in asthmatic mice. European Journal of Clinical Microbiology & Infectious Diseases. 40 (8): 1623–1631.CrossRef

68.

Simon Machado, R., K. Mathias, L. Joaquim, R. Willig de Quadros, F. Petronilho, and G.T. Rezin. 2023. From diabetic hyperglycemia to cerebrovascular damage: a narrative review. Brain Research 1821: 148611.PubMedCrossRef

69.

Yedke, N.G., S. Upadhayay, R. Singh, S. Jamwal, S.F. Ahmad, and P. Kumar. 2023. Bacillus Calmette-Guérin vaccine attenuates haloperidol-induced TD-like behavioral and neurochemical alteration in experimental rats. Biomolecules 13 (11): 1667.PubMedPubMedCentralCrossRef

70.

Dow, C.T., C.L. Greenblatt, E.D. Chan, and J.F. Dow. 2022. Evaluation of BCG vaccination and plasma amyloid: a prospective, pilot study with implications for Alzheimer’s disease. Microorganisms. 10 (2): 424.PubMedPubMedCentralCrossRef

71.

Klein, B.Y., C.L. Greenblatt, O.N. Gofrit, and H. Bercovier. 2022. Bacillus Calmette-Guérin in immuno-regulation of Alzheimer’s disease. Front Aging Neurosci. 27: 14.

72.

Klinger, D., B.L. Hill, N. Barda, E. Halperin, O.N. Gofrit, C.L. Greenblatt, et al. 2021. Bladder cancer immunotherapy by BCG is associated with a significantly reduced risk of Alzheimer’s disease and Parkinson’s disease. Vaccines (Basel). 9 (5): 491.PubMedPubMedCentralCrossRef

73.

Li, Q., X. Wang, Z.H. Wang, Z. Lin, J. Yang, J. Chen, et al. 2022. Changes in dendritic complexity and spine morphology following BCG immunization in APP/PS1 mice. Human Vaccines & Immunotherapeutics 18 (6).

74.

Zuo, Z., F. Qi, J. Yang, X. Wang, Y. Wu, Y. Wen, et al. 2017. Immunization with Bacillus Calmette-Guérin (BCG) alleviates neuroinflammation and cognitive deficits in APP/PS1 mice via the recruitment of inflammation-resolving monocytes to the brain. Neurobiology of Diseases 101: 27–39.CrossRef

75.

Barichello, T., J.S. Generoso, L.R. Simões, J.A. Goularte, F. Petronilho, P. Saigal, et al. 2016. Role of microglial activation in the pathophysiology of bacterial meningitis. Molecular Neurobiology 53 (3): 1770–1781.PubMedCrossRef

76.

Laćan, G., H. Dang, B. Middleton, M.A. Horwitz, J. Tian, W.P. Melega, et al. 2013. Bacillus Calmette-Guerin vaccine-mediated neuroprotection is associated with regulatory T-cell induction in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease. Journal of Neuroscience Research 91 (10): 1292–1302.PubMedPubMedCentralCrossRef

77.

Witschkowski, J., J. Behrends, R. Frank, L. Eggers, L. von Borstel, D. Hertz, et al. 2020. BCG Provides short-term protection from experimental cerebral malaria in mice. Vaccines (Basel). 8 (4): 745.PubMedPubMedCentralCrossRef

78.

Kulkarni, S., S. Mukherjee, A. Pandey, R. Dahake, U. Padmanabhan, and A.S. Chowdhary. 2016. Bacillus Calmette-Guérin Confers neuroprotection in a murine model of Japanese encephalitis. NeuroImmunoModulation 23 (5–6): 278–286.PubMedCrossRef

79.

Yang, J., F. Qi, and Z. Yao. 2016. Neonatal Bacillus Calmette-Guérin vaccination alleviates lipopolysaccharide-induced neurobehavioral impairments and neuroinflammation in adult mice. Molecular Medicine Reports 14 (2): 1574–1586.PubMedPubMedCentralCrossRef

80.

Yang, J., F. Qi, H. Gu, J. Zou, Y. Yang, Q. Yuan, et al. 2016. Neonatal BCG vaccination of mice improves neurogenesis and behavior in early life. Brain Research Bulletin 120: 25–33.PubMedCrossRef

81.

Cossu, D., K. Yokoyama, Y. Tomizawa, E. Momotani, and N. Hattori. 2017. Altered humoral immunity to mycobacterial antigens in Japanese patients affected by inflammatory demyelinating diseases of the central nervous system. Scientific Reports 7 (1): 3179.PubMedPubMedCentralCrossRef

82.

Ristori, G., M.G. Buzzi, U. Sabatini, E. Giugni, S. Bastianello, F. Viselli, et al. 1999. Use of Bacille Calmette-Guèrin (BCG) in multiple sclerosis. Neurology 53 (7): 1588–1588.PubMedCrossRef

83.

Paolillo, A., M.G. Buzzi, E. Giugni, U. Sabatini, S. Bastianello, C. Pozzilli, et al. 2003. The effect of Bacille Calmette-Guérin on the evolution of new enhancing lesions to hypointense T1 lesions in relapsing remitting MS. Journal of Neurology 250 (2): 247–248.PubMedCrossRef

84.

Cossu, D., K. Yokoyama, T. Sakanishi, L.A. Sechi, and N. Hattori. 2023. Bacillus Calmette-Guérin Tokyo-172 vaccine provides age-related neuroprotection in actively induced and spontaneous experimental autoimmune encephalomyelitis models. Clinical and Experimental Immunology 212 (1): 70–80.PubMedPubMedCentralCrossRef

85.

Keefe, R.C., H. Takahashi, L. Tran, K. Nelson, N. Ng, W.M. Kühtreiber, et al. 2021. BCG therapy is associated with long-term, durable induction of Treg signature genes by epigenetic modulation. Scientific Reports 11 (1): 14933.PubMedPubMedCentralCrossRef

86.

Ristori, G., D. Faustman, G. Matarese, S. Romano, and M. Salvetti. 2018. Bridging the gap between vaccination with Bacille Calmette-Guérin (BCG) and immunological tolerance: the cases of type 1 diabetes and multiple sclerosis. Current Opinion in Immunology 55: 89–96.PubMedCrossRef

87.

Gonzalez-Pena, D., S.E. Nixon, J.C. O’Connor, B.R. Southey, M.A. Lawson, R.H. McCusker, et al. 2016. Microglia transcriptome changes in a model of depressive behavior after immune challenge. PLoS One1 11 (3).CrossRef

88.

Cao, D.H., J.C. Wang, J. Liu, Y.T. Du, L.W. Cui, and Y.M. Cao. 2016. Bacillus Calmette-Guerin-inoculation at different time points influences the outcome of C57BL/6 mice infected with Plasmodium chabaudi chabaudi AS. Folia Parasitol (Praha). 1: 63.

89.

Elvang, T., J.P. Christensen, R. Billeskov, T. Thi Kim Thanh, P. Holst, A.R. Thomsen, et al. 2009. CD4 and CD8 T cell responses to the M. tuberculosis Ag85B-TB10.4 promoted by adjuvanted subunit, adenovector or heterologous prime boost vaccination. PLoS One 4 (4): e5139.PubMedPubMedCentralCrossRef

90.

Falke, J., J. Parkkinen, L. Vaahtera, C.A. Hulsbergen-van de Kaa, E. Oosterwijk, and J.A. Witjes. 2018. Curcumin as treatment for bladder cancer: a preclinical study of cyclodextrin-curcumin complex and BCG as intravesical treatment in an orthotopic bladder cancer rat model. BioMed Research International 2018: 1–7.CrossRef

91.

Ferraz, J.C., E. Stavropoulos, M. Yang, S. Coade, C. Espitia, D.B. Lowrie, et al. 2004. A heterologous DNA priming-Mycobacterium bovis BCG boosting immunization strategy using mycobacterial Hsp70, Hsp65, and Apa antigens improves protection against tuberculosis in mice. Infection and Immunity 72 (12): 6945–6950.PubMedPubMedCentralCrossRef

92.

Fitzpatrick, M., M.M. Ho, S. Clark, B. Dagg, B. Khatri, F. Lanni, et al. 2019. Comparison of pellicle and shake flask-grown BCG strains by quality control assays and protection studies. Tuberculosis 114: 47–53.PubMedCrossRef

93.

Gomes-Giacoia, E., M. Miyake, S. Goodison, A. Sriharan, G. Zhang, L. You, et al. 2014. Intravesical ALT-803 and BCG treatment reduces tumor burden in a carcinogen induced bladder cancer rat model; a role for cytokine production and NK cell expansion. PLoS One1 9 (6): e96705.CrossRef

94.

Hogarth, P.J., K.E. Logan, J.C. Ferraz, R.G. Hewinson, and M.A. Chambers. 2006. Protective efficacy induced by Mycobacterium bovis bacille Calmette-Guèrin can be augmented in an antigen independent manner by use of non-coding plasmid DNA. Vaccine. 24 (1): 95–101.PubMedCrossRef

95.

Huang, P., C. Ma, P. Xu, K. Guo, A. Xu, and C. Liu. 2015. Efficacy of intravesical Bacillus Calmette-Guérin therapy against tumor immune escape in an orthotopic model of bladder cancer. Experimental and Therapeutic Medicine 9 (1): 162–166.PubMedCrossRef

96.

Kolibab, K., A. Yang, S.C. Derrick, T.A. Waldmann, L.P. Perera, and S.L. Morris. 2010. Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant. Clinical and Vaccine Immunology. 17 (5): 793–801.PubMedPubMedCentralCrossRef

97.

Lombardo, K.A., A. Obradovic, A.K. Singh, J.L. Liu, G. Joice, M. Kates, et al. 2022. BCG invokes superior STING-mediated innate immune response over radiotherapy in a carcinogen murine model of urothelial cancer. The Journal of Pathology 256 (2): 223–234.PubMedCrossRef

98.

McShane, H., R. Brookes, S.C. Gilbert, and A.V.S. Hill. 2001. Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis. Infection and Immunity 69 (2): 681–686.PubMedPubMedCentralCrossRef

99.

Romano, M., S. Dsouza, P. Adnet, R. Laali, F. Jurion, K. Palfliet, et al. 2006. Priming but not boosting with plasmid DNA encoding mycolyl-transferase Ag85A from Mycobacterium tuberculosis increases the survival time of Mycobacterium bovis BCG vaccinated mice against low dose intravenous challenge with M. tuberculosis H37Rv. Vaccine. 24 (16): 3353–3364.PubMedCrossRef

100.

Skinner, M.A., A.J. Ramsay, G.S. Buchan, D.L. Keen, C. Ranasinghe, L. Slobbe, et al. 2003. A DNA prime-live vaccine boost strategy in mice can augment IFN-γ responses to mycobacterial antigens but does not increase the protective efficacy of two attenuated strains of Mycobacterium bovis against bovine tuberculosis. Immunology 108 (4): 548–555.PubMedPubMedCentralCrossRef

101.

Song, D., F. Qi, S. Liu, Z. Tang, J. Duan, and Z. Yao. 2020. The adoptive transfer of BCG-induced T lymphocytes contributes to hippocampal cell proliferation and tempers anxiety-like behavior in immune deficient mice. PLoS One 15 (4): e0225874.PubMedPubMedCentralCrossRef

102.

Tkachuk, A.P., V.A. Gushchin, V.D. Potapov, A.V. Demidenko, V.G. Lunin, and A.L. Gintsburg. 2017. Multi-subunit BCG booster vaccine GamTBvac: assessment of immunogenicity and protective efficacy in murine and guinea pig TB models. PLoS One 12 (4): e0176784.PubMedPubMedCentralCrossRef

103.

Uranga, S., D. Marinova, C. Martin, and N. Aguilo. 2016. Protective efficacy and pulmonary immune response following subcutaneous and intranasal BCG administration in mice. Journal of Visualized Experiments (115).

104.

Pedras-Vasconcelos, J.A., Y. Chapdelaine, R. Dudani, H. van Faassen, D.K. Smith, and S. Sad. 2002. Mycobacterium bovis BCG-infected mice are more susceptible to staphylococcal enterotoxin B-mediated toxic shock than uninfected mice despite reduced in vitro splenocyte responses to superantigens. Infection and Immunity 70 (8): 4148–4157.PubMedPubMedCentralCrossRef

105.

Xu, H., Y. Jia, Y. Li, C. Wei, W. Wang, R. Guo, et al. 2019. IL-10 Dampens the Th1 and Tc activation through modulating DC functions in BCG vaccination. Mediators of Inflammation 12 (2019): 1–10.

106.

Zhou, H., X. Lu, J. Huang, P. Jordan, S. Ma, L. Xu, et al. 2022. Induction of trained immunity protects neonatal mice against microbial sepsis by boosting both the inflammatory response and antimicrobial activity. Journal of Inflammation Research 15: 3829–3845.PubMedPubMedCentralCrossRef

Titel: Bacillus Calmette-Guérin (BCG)-Induced Protection in Brain Disorders
verfasst von: Khiany Mathias
Richard Simon Machado
Solange Stork
Carla Damasio Martins
Amanda Christine da Silva Kursancew
Victória Linden de Rezende
Cinara Ludvig Gonçalves
Tatiana Barichello
Josiane Somariva Prophiro
Fabricia Petronilho
Publikationsdatum: 26.04.2024
Verlag: Springer US
Erschienen in: Inflammation
Print ISSN: 0360-3997
Elektronische ISSN: 1573-2576
DOI: https://doi.org/10.1007/s10753-024-02018-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Bei Herzinsuffizienz muss „Eisenmangel“ neu definiert werden!

16.05.2024 Herzinsuffizienz Nachrichten

Bei chronischer Herzinsuffizienz macht es einem internationalen Expertenteam zufolge wenig Sinn, die Diagnose „Eisenmangel“ am Serumferritin festzumachen. Das Team schlägt vor, sich lieber an die Transferrinsättigung zu halten.

Herzinfarkt mit 85 – trotzdem noch intensive Lipidsenkung?

16.05.2024 Hypercholesterinämie Nachrichten

Profitieren nach einem akuten Myokardinfarkt auch Betroffene über 80 Jahre noch von einer intensiven Lipidsenkung zur Sekundärprävention? Um diese Frage zu beantworten, wurden jetzt Registerdaten aus Frankreich ausgewertet.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen